盐酸氮卓斯汀(Azelastine Hydrochloride) - 药物靶点：H1 receptor_在研适应症：呼吸道感染，常年性变应性鼻炎，季节性过敏性鼻炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名

4-(p-Chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-phthalazinone、Afluon、Allergodil

+ [29]

靶点

H1 receptor

作用方式

拮抗剂、稳定剂

作用机制

H1 receptor拮抗剂(组胺H1受体拮抗剂)、肥大细胞稳定剂

治疗领域

免疫系统疾病感染耳鼻咽喉疾病+ [2]

在研适应症

呼吸道感染常年性变应性鼻炎季节性过敏性鼻炎+ [7]

非在研适应症

慢性鼻炎变应性结膜炎常年过敏性结膜炎+ [2]

原研机构

Mylan, Inc.

在研机构

Viatris Pty Ltd.

Eisai Co., Ltd.

Meda Pharma GmbH & Co. KG

+ [2]

非在研机构

Meda Pharmaceuticals, Inc.NORVIUM BIOSCIENCE

Bayer AG

最高研发阶段批准上市

首次获批日期

日本 (1986-04-30),

哮喘过敏性鼻炎

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C22H25Cl2N3O

InChIKeyYEJAJYAHJQIWNU-UHFFFAOYSA-N

CAS号79307-93-0

关联

38

项与盐酸氮卓斯汀相关的临床试验

CTRI/2023/10/059139

/ Not yet recruiting临床1/2期IIT

A randomized controlled clinical trial to evaluate the efficacy of Anutaila Nasya and Azelastine Nasal Spray in management of Vataj Pratishyaya. - Nil

开始日期2023-11-10

申办/合作机构-

NCT06126952

/ Completed临床2期

Randomized, Double-blind, Cross-over Clinical Trial to Assess Onset of Action and Efficacy of Azelastine Hydrochloride 0.15% Nasal Spray in the Treatment of Allergen-Induced Allergic Rhinitis Symptoms in an Environmental Exposure Unit in Comparison to Placebo and Mometasone Furoate/Olopatadine Hydrochloride Nasal Spray

This study is to assess the Onset of Action and Efficacy of azelastine hydrochloride 0.15% in treating the nasal symptoms of seasonal allergic rhinitis (SAR) induced by an allergen challenge in an Environmental Exposure Unit (EEU) followed by a single dose and a 3-day treatment at home.

开始日期2023-10-30

申办/合作机构

Meda Pharma GmbH & Co. KG

NCT05887843

/ Terminated临床1期

An Open-label, Single-Dose, Three-way Crossover Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in Adolescents (12 to 17 Years of Age) and Young Adults (18 to 24 Years of Age) With Seasonal Allergic Rhinitis

This study will compare the PK parameters of the combination test formulation to monotherapy reference products (mometasone furoate and azelastine hydrochloride) in adolescents and young adult patients with seasonal allergic rhinitis.

开始日期2023-06-08

申办/合作机构

Sandoz International GmbH

100 项与盐酸氮卓斯汀相关的临床结果

登录后查看更多信息

100 项与盐酸氮卓斯汀相关的转化医学

登录后查看更多信息

100 项与盐酸氮卓斯汀相关的专利（医药）

登录后查看更多信息

873

项与盐酸氮卓斯汀相关的文献（医药）

2025-03-01·Clinical Pharmacology in Drug Development

Determination of the Bioavailability of 3 Intranasal Formulations of Azelastine Hydrochloride in Healthy Male Volunteers

Article

作者: Canonica, Georgio Walter ; Berger, William E. ; Klimek, Ludger ; Bousquet, Jean ; Nguyen, Duc Tung ; Ramalingam, Rajesh Kumar ; Liu, Mark

AbstractThe primary objective of the study was to determine the bioavailability of 2 new formulations of azelastine (AZE) hydrochloride (0.10% and 0.15% AZE) containing sorbitol and sucralose compared with the commercially available 0.10% AZE. This study was performed in healthy volunteers based on the pharmacokinetic parameters maximum plasma concentration and area under the plasma concentration–time curve from time zero to the last measurable concentration. This was a Phase 1, open‐label, single‐center, randomized, parallel‐group study. Subjects were randomized to 1 of 3 treatment groups: (1) 0.10% AZE (treatment A), (2) 0.15% AZE (treatment B) (Groups 1 and 2 both containing sorbitol and sucralose), and (3) the commercially available 0.10% AZE (treatment C). A total of 54 subjects were randomized and received treatment A, B, or C. Maximum plasma concentration and area under the plasma concentration–time curve were similar when compared in treatments A and C (0.1%) for AZE and its metabolite, desmethylazelastine. The most frequently reported adverse events were rhinorrhea (5.6%) and sneezing (5.6%).

2025-03-01·European Journal of Medicinal Chemistry

Repurposing FDA-approved drugs to target G-quadruplexes in breast cancer

Article

作者: Marzano, Simona ; Randazzo, Antonio ; Landolfi, Laura ; Catalanotti, Bruno ; Malfitano, Anna Maria ; Pagano, Bruno ; Moraca, Federica ; Castellano, Giuliano ; Napolitano, Fabiana ; Arciuolo, Valentina ; Di Porzio, Anna ; D'Aria, Federica ; Amato, Jussara

Breast cancer, a leading cause of cancer-related mortality in women, is characterized by genomic instability and aberrant gene expression, often influenced by noncanonical nucleic acid structures such as G-quadruplexes (G4s). These structures, commonly found in the promoter regions and 5'-untranslated RNA sequences of several oncogenes, play crucial roles in regulating transcription and translation. Stabilizing these G4 structures offers a promising therapeutic strategy for targeting key oncogenic pathways. In this study, we employed a drug repurposing approach to identify FDA-approved drugs capable of binding and stabilizing G4s in breast cancer-related genes. Using ligand-based virtual screening and biophysical methods, we identified several promising compounds, such as azelastine, belotecan, and irinotecan, as effective G4 binders, with significant antiproliferative effects in breast cancer cell lines. Notably, belotecan and irinotecan exhibited a synergistic mechanism, combining G4 stabilization with their established topoisomerase I inhibition activity to enhance cytotoxicity in cancer cells. Our findings support the therapeutic potential of G4 stabilization in breast cancer, validate drug repurposing as an efficient strategy to identify G4-targeting drugs, and highlight how combining G4 stabilization with other established drug activities may improve anticancer efficacy.

2025-03-01·Clinical & Experimental Allergy

Adherence to Treatment in Allergic Rhinitis During the Pollen Season in Europe: A MASK‐air Study

Article

作者: Papadopoulos, Nikolaos G. ; Del Giacco, Stefano ; Kvedariene, Violeta ; Iinuma, Tomohisa ; Regateiro, Frederico S. ; Bedbrook, Anna ; Mösges, Ralph ; Sova, Milan ; Sousa‐Pinto, Bernardo ; Zuberbier, Torsten ; Ventura, Maria Teresa ; Pham‐Thi, Nhân ; Bergmann, Karl C. ; Cardona, Victoria ; Gemicioglu, Bilun ; Rouadi, Philip W. ; Laune, Daniel ; Cruz, Alvaro A. ; Kuna, Piotr ; Niedoszytko, Marek ; Vieira, Rafael José ; Larenas‐Linnemann, Desiree E. ; Devillier, Philippe ; Bousquet, Jean ; Cherrez‐Ojeda, Ivan ; Samolinski, Boleslaw ; Louis, Renaud ; Toppila‐Salmi, Sanna K. ; Pfaar, Oliver ; Sastre, Joaquin ; Czarlewski, Wienczyslawa ; Kraxner, Helga ; Reitsma, Sietze ; Pereira, Ana Margarida ; Ansotegui, Ignacio J. ; Fokkens, Wytske J. ; Taborda‐Barata, Luis ; Fonseca, Joao A. ; Ivancevich, Juan Carlos ; Costa, Elísio M. ; Robles‐Velasco, Karla ; Amaral, Rita ; Haahtela, Tari ; Canonica, G. Walter ; Cingi, Cemal ; Makris, Michael ; Brussino, Luisa ; Zidarn, Mihaela ; Klimek, Ludger ; Patella, Vincenzo ; Yorgancioglu, Arzu ; Morais‐Almeida, Mario ; Cecchi, Lorenzo ; Valiulis, Arunas

ABSTRACTBackgroundAdherence to rhinitis treatment has been insufficiently assessed. We aimed to use data from the MASK‐air mHealth app to assess adherence to oral antihistamines (OAH), intra‐nasal corticosteroids (INCS) or azelastine‐fluticasone in patients with allergic rhinitis.MethodsWe included regular European MASK‐air users with self‐reported allergic rhinitis and reporting at least 1 day of OAH, INCS or azelastine‐fluticasone. We assessed weeks during which patients answered the MASK‐air questionnaire on all days. We restricted our analyses to data provided between January and June, to encompass the pollen seasons across the different assessed countries. We analysed symptoms using visual analogue scales (VASs) and the combined symptom‐medication score (CSMS), performing stratified analyses by weekly adherence levels. Medication adherence was computed as the proportion of days in which patients reported rhinitis medication use. Sensitivity analyses were performed considering all weeks with at most 1 day of missing data and all months with at most 4 days of missing data.ResultsWe assessed 8212 complete weeks (1361 users). Adherence (use of medication > 80% days) to specific drug classes ranged from 31.7% weeks for azelastine‐fluticasone to 38.5% weeks for OAH. Similar adherence to rhinitis medication was found in users with or without self‐reported asthma, except for INCS (better adherence in asthma patients). VAS and CSMS levels increased from no adherence to full adherence, except for INCS. A higher proportion of days with uncontrolled symptoms was observed in weeks with higher adherence. In full adherence weeks, 41.2% days reported rhinitis co‐medication. The sensitivity analyses displayed similar results.ConclusionsA high adherence was found in patients reporting regular use of MASK‐air. Different adherence patterns were found for INCS compared to OAH or azelastine‐fluticasone that are likely to impact guidelines.

38

项与盐酸氮卓斯汀相关的新闻（医药）

2025-03-04

·米内网

【关注】7亿注射剂，海南药企获批

精彩内容日前，国家药监局官网显示，海南斯达制药的苯磺顺阿曲库铵注射液以仿制4类报产获批，视同过评。米内网数据显示，苯磺顺阿曲库铵注射液在2023年中国公立医疗机构终端销售额7亿元，2024年上半年同比增长2.00%，是肌肉松弛药（化+生）TOP1产品。今年以来，海南斯达制药已有4款产品获批，4款产品报产在审。来源：米内网一键检索苯磺顺阿曲库铵注射液用于手术和其他操作以及重症监护治疗，作为全麻的辅助用药或在重症监护病房(ICU)起镇静作用，它可以松弛骨骼肌，使气管插管和机械通气易于进行。近年中国公立医疗机构终端苯磺顺阿曲库铵注射液销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局苯磺顺阿曲库铵注射液在2023年中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端销售额7亿元，2024年上半年同比增长2.00%，是肌肉松弛药（化+生）TOP1产品。米内网数据显示，苯磺顺阿曲库铵注射液有18家企业拥有生产批文，海南斯达制药、浙江仙琚制药、四川汇宇制药等17家过评，吉林天成制药、本溪恒康制药、山东威智百科药业等4家均以仿制4类报产在审，获批后视同过评。海南斯达制药今年以来获批产品来源：米内网中国申报进度（MED）数据库今年以来，海南斯达制药已有4款产品获批上市，左氧氟沙星注射液、盐酸丙卡特罗吸入溶液、盐酸氮卓斯汀滴眼液、硫酸镁钠钾口服用浓溶液报产在审，涵盖肌肉-骨骼系统、心脑血管系统药物、呼吸系统用药等多个治疗大类。资料来源：国家药监局官网、米内网数据库注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

上市批准

2025-02-26

·医药观澜

3分钟起效！兆科眼科与视方极医药联合发布过敏性结膜炎治疗滴眼液新方案

▎药明康德内容团队报道 2月25日，兆科眼科宣布，其全资附属子公司兆科（广州）眼科药物有限公司与眼科医药创新型企业浙江视方极医药科技有限公司（“视方极＂）联合发布单剂量不含抑菌剂的盐酸氮䓬斯汀滴眼液产品，为过敏性结膜炎患者提供更全面的治疗方案选择。新闻稿表示，近年来，中国过敏性结膜炎的发病率逐年上升。盐酸氮䓬斯汀滴眼液的推出有望为广大过敏性结膜炎患者带来新的希望，其3分钟迅速起效，持续时间长达10小时。0.4毫升单支装不添加抑菌剂，更适合长期治疗的慢性反复发作患者。该产品的成功上市不仅有助于进一步满足临床用药需求，也为过敏性结膜炎患者提供了优质的治疗选择。视方极医药于2021年成立于浙江杭州，该公司重点布局眼科药物研发与产业化，产品管线覆盖近视防控、糖尿病视网膜病变、干眼、视疲劳、过敏性结膜炎、眼部感染、非感染性眼部炎症、眼科表面麻醉等治疗领域。兆科眼科成立于2017年，致力于眼科疗法的研发、生产及商业化。该公司已建立起由创新药及仿制药组成的候选药物，涵盖影响眼前节及眼后节的主要眼科适应症。目前，该公司正专注于主要药物的近期发展计划，包括处于新药申请阶段的环孢素A眼凝胶、NVK002，处于关键3期临床试验阶段的TAB014，及处于关键3期临床试验准备阶段的BRIMOCHOLTM PF、ZKY001，共涵盖五种主要眼科疾病，即干眼症、近视、年龄相关性黄斑变性、老花眼和角膜上皮缺损。参考资料： [1]兆科眼科与视方极联合发布单剂量盐酸氮䓬斯汀滴眼液（顺敏®）过敏性结膜炎治疗添加新方案.Retrieved Feb 25, 2025, from https://mp.weixin.qq.com/s/WePtMcMKxLSCezr0-FVhQQ 本文由药明康德内容团队根据公开资料整理编辑，欢迎个人转发至朋友圈。转发授权或其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

临床3期

2025-02-24

·novaken.cn

精彩汇聚，创新绽放|广州新济药业在第十五届泰州医博会上圆满闭幕

2024年11月29日至30日，为期两天的医药行业的盛会在泰州这座充满活力的城市划上句号。在这里，我们对所有支持和信任我们的客户表达最诚挚的感谢！广州新济的参展亮点新济药业已建设吸入制剂技术平台，具备了鼻喷雾剂开发所需的关键设备及方法，掌握了定向、精准、高效的鼻喷雾剂给药递送技术。目前，新济药业已具有鼻喷雾剂仿制开发的丰富品种经验，包括糠酸莫米松鼻喷雾剂、盐酸氮卓斯汀鼻喷雾剂等。同时，新济药业还具备包括鼻喷雾剂在内的各类改良新药的开发能力和经验，如用于神经退行性疾病的鼻喷雾剂改良新药XJN010近期已获临床批件，目前正承接各类改良新药业务。广州新济药业科技有限公司广州新济药业是从事创新制剂新药和高端复杂制剂开发的高新技术企业。由国家重大人才工程特聘专家、国家药典委员会委员吴传斌博士创办，其核心管理团队具有多年跨国公司及知名药企管理和产业化经验，成功研发数十个高端药物制剂产品在中美上市。公司依托六大核心技术平台，可为国内外客户提供优质和全方位的研发技术服务。

100 项与盐酸氮卓斯汀相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00659	盐酸氮卓斯汀	R01AC03 R06AX19 S01GX07	DB00972

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
呼吸道感染	美国	Bayer HealthCare AG	2021-06-17
常年性变应性鼻炎	澳大利亚	Viatris Pty Ltd.	2004-07-21
季节性过敏性鼻炎	澳大利亚	Viatris Pty Ltd.	2004-07-21
皮炎	日本	Eisai Co., Ltd.	1990-08-30
湿疹	日本	Eisai Co., Ltd.	1990-08-30
痒疹	日本	Eisai Co., Ltd.	1990-08-30
瘙痒	日本	Eisai Co., Ltd.	1990-08-30
荨麻疹	日本	Eisai Co., Ltd.	1990-08-30
哮喘	日本	Eisai Co., Ltd.	1986-04-30
过敏性鼻炎	日本	Eisai Co., Ltd.	1986-04-30

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
过敏性鼻炎	药物发现	美国	NORVIUM BIOSCIENCE	2008-10-15
常年性变应性鼻炎	药物发现	美国	NORVIUM BIOSCIENCE	2008-10-15
常年过敏性结膜炎	药物发现	美国	Meda Pharmaceuticals, Inc.	2007-01-01
慢性鼻炎	药物发现	美国	Meda Pharmaceuticals, Inc.	2006-07-01
季节性过敏性鼻炎	药物发现	美国	NORVIUM BIOSCIENCE	1996-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04264637 (Pubmed \| Ann Allergy Asthma Immunol) 人工标引	临床3期	过敏性鼻炎	110	Azelastine HCl 0.15% nasal spray	(顧壓網艱鹹鹹鬱簾製繭) = 糧餘壓製鏇淵膚簾醖艱膚糧範範襯夢憲網範製 (鏇觸範襯顧憲獵壓淵鏇 )	积极	2024-07-01
NCT00712920 (Pubmed)	临床3期	常年性变应性鼻炎	581	0.10% Azelastine hydrochloride	餘觸鹽襯窪鏇蓋窪網蓋(襯鏇餘夢夢觸鏇繭鬱鬱) = 網簾餘鬱壓衊艱襯膚膚膚壓積襯選齋願鏇窪窪 (製鬱餘糧獵醖淵製顧遞, 3.99)	积极	2023-01-01
				0.15% Azelastine hydrochloride	餘觸鹽襯窪鏇蓋窪網蓋(襯鏇餘夢夢觸鏇繭鬱鬱) = 廠顧簾顧蓋簾廠鬱餘鏇膚壓積襯選齋願鏇窪窪 (製鬱餘糧獵醖淵製顧遞, 4.26)
ONSET OF ACTION OF AZELASTINE HCL NASAL SPRAY 0.15% (ACAAI2022)	N/A	-	110	Azelastine HCl 0.15%	積鏇製襯襯餘願鏇網範(鏇齋簾夢蓋衊觸鹹餘窪) = 築糧鹽顧網艱鬱顧簾觸淵醖艱衊繭願衊壓衊獵 (襯鬱餘簾憲築築積糧鏇 )	积极	2022-11-10
Pubmed 人工标引	临床4期	结膜疾病	111	Fluorometholone+Azelastine	(艱積願鏇遞廠夢窪鹽廠) = 鏇願範鑰憲遞積衊簾選襯網醖糧顧簾觸網齋憲 (積觸繭繭觸獵膚壓築遞, 2.19) 更多	积极	2022-07-04
				Fluorometholone	(艱積願鏇遞廠夢窪鹽廠) = 廠獵壓積壓鬱窪築廠窪襯網醖糧顧簾觸網齋憲 (積觸繭繭觸獵膚壓築遞, 8.46) 更多
AAAAI2018	N/A	过敏性鼻炎	-	Fluticasone propionate/Azelastine hydrochloride	廠壓遞醖齋醖襯繭窪繭(選構鏇鹽範蓋繭構顧壓) = 鬱鹹鏇網製蓋鹹築鏇衊獵製鑰窪積齋窪網夢簾 (遞窪繭遞獵製齋鑰選網 )	-	2018-02-01
				Fluticasone propionate	廠壓遞醖齋醖襯繭窪繭(選構鏇鹽範蓋繭構顧壓) = 繭窪遞網鏇鑰選構範窪獵製鑰窪積齋窪網夢簾 (遞窪繭遞獵製齋鑰選網 )
NCT01915823 (CTgov)	临床3期	季节性过敏性鼻炎 \| 季节性鼻炎	348	azelastine hydrochloride (Dymista)	鏇衊顧衊衊餘蓋選鏇構(憲糧膚醖積齋艱範網膚) = 齋顧醖憲壓顧壓獵鏇糧糧鹹醖獵艱鹹鹹餘製憲 (顧餘觸鬱壓網艱窪醖鹹, 願夢鹽構淵繭鬱艱簾餘 ~ 鏇遞簾廠糧鹹鹽淵艱顧) 更多	-	2015-06-29
				Dymista vehicle (Dymista Vehicle)	鏇衊顧衊衊餘蓋選鏇構(憲糧膚醖積齋艱範網膚) = 範齋繭艱築艱膚鏇簾窪糧鹹醖獵艱鹹鹹餘製憲 (顧餘觸鬱壓網艱窪醖鹹, 鏇構廠衊鏇鹹憲選襯選 ~ 鬱衊繭窪遞醖醖壓齋範) 更多
NCT01880840 (CTgov)	临床4期	过敏性鼻炎	191	205.5 mcg of azelastine hydrochloride (Astepro 0.15% Nasal Spray)	(艱淵鏇願齋構簾顧膚鑰) = 糧衊願醖鏇繭壓窪膚觸積遞遞獵顧選遞衊積鹽 (網顧鹹獵鏇鹹艱壓鹽糧, 襯窪齋顧膚觸繭顧遞範 ~ 衊網簾獵選鹹襯齋鹹廠) 更多	-	2015-06-29
				137 mcg of azelastine hydrochloride (Astepro 0.1% Nasal Spray)	(艱淵鏇願齋構簾顧膚鑰) = 鹹齋鑰衊襯夢憲簾襯夢積遞遞獵顧選遞衊積鹽 (網顧鹹獵鏇鹹艱壓鹽糧, 鏇夢夢繭簾膚選築簾蓋 ~ 築醖膚艱衊築鏇鑰廠膚) 更多
AAAAI2015	N/A	季节性过敏性鼻炎	-	Azelastine HCl/Fluticasone Propionate Nasal Spray	艱獵餘構廠選衊夢蓋膚(齋艱淵觸夢襯窪鏇網顧) = 廠積遞獵選構醖簾餘夢壓鹹膚醖顧願蓋鏇窪鹹 (齋憲遞蓋窪積簾鹽廠醖, -0.41 ~ -0.21)	积极	2015-02-01
				Azelastine HCl	艱獵餘構廠選衊夢蓋膚(齋艱淵觸夢襯窪鏇網顧) = 壓艱齋遞醖艱選餘網鏇壓鹹膚醖顧願蓋鏇窪鹹 (齋憲遞蓋窪積簾鹽廠醖, -0.30 ~ -0.10)
NCT00651118 (CTgov)	临床3期	季节性过敏性鼻炎	832	fluticasone propionate (Fluticasone Propionate)	艱艱構窪獵襯繭選膚壓(夢壓範憲膚壓膚顧繭鏇) = 願齋醖憲鑰夢膚廠鬱簾醖遞憲築鏇餘鑰積齋遞 (夢築醖築簾範願齋襯繭, 觸醖製襯糧選鬱鏇糧齋 ~ 製淵顧膚製鑰繭夢願鹹) 更多	-	2012-09-26
				azelastine Hcl (Azelastine HCl)	艱艱構窪獵襯繭選膚壓(夢壓範憲膚壓膚顧繭鏇) = 鏇艱簾蓋範壓簾蓋製選醖遞憲築鏇餘鑰積齋遞 (夢築醖築簾範願齋襯繭, 窪餘窪範餘網蓋鬱壓鹽 ~ 糧廠繭壓積網選憲獵繭) 更多
NCT00883168 (CTgov)	临床3期	季节性过敏性鼻炎	1,791	azelastineHcl (Azelastine Hcl)	淵窪築醖網鏇淵窪構構(網窪廠構夢選範積襯壓) = 選齋鹹鏇遞糧製鏇窪糧壓襯遞鏇鑰餘鑰製範窪 (顧夢憲簾壓襯繭憲製餘, 遞鑰構鹽願遞願網獵艱 ~ 築夢齋鏇艱網築蓋窪鑰) 更多	-	2012-09-07
				fluticasone propionate (Fluticasone Propionate)	淵窪築醖網鏇淵窪構構(網窪廠構夢選範積襯壓) = 艱襯願築顧獵餘蓋淵獵壓襯遞鏇鑰餘鑰製範窪 (顧夢憲簾壓襯繭憲製餘, 膚膚齋網簾壓廠積簾艱 ~ 積齋餘衊願觸遞醖顧範) 更多